Stimuli-Responsive Nanocarrier for Co-delivery of MiR-31 and Doxorubicin to Suppress High MtEF4 Cancer

Fang Wang,Lingyun Zhang,Xiufeng Bai,Xintao Cao,Xiangyu Jiao,Yan Huang,Yansheng Li,Yan Qin,Yongqiang Wen

DOI: https://doi.org/10.1021/acsami.8b07698

IF: 9.5

2018-01-01

ACS Applied Materials & Interfaces

Abstract:Gene interference-based therapeutics represent a fascinating challenge and show enormous potential for cancer treatment, in which microRNA is used to correct abnormal gene. On the basis of the above, we introduced microRNA-31 to bind to 3'-untranslated region of mtEF4, resulting in the downregulation of its messenger RNA and protein to trigger cancer cells apoptosis through mitochondria-related pathway. To achieve better therapeutic effect, a mesoporous silica nanoparticle-based controlled nanoplatform had been developed. This system was fabricated by conjugation of microRNA-31 onto doxorubicin-loaded mesoporous silica nanoparticles with a poly(ethyleneimine)/hyaluronic acid coating, and drug release was triggered by acidic environment of tumors. By feat of surface functionalization and tumor-specific conjugation to nanoparticles, our drug delivery system could promote intracellular accumulation of drugs via the active transport at tumor site. More importantly, microRNA-31 not only directly targeted to mtEF4 to promote cell's death, but had synergistic effects when used in combination with doxorubicin, and achieved excellent superadditive effects. As such, our research might provide new insights toward detecting high mtEF4 cancer and exploiting highly effective anticancer drugs.